Johnson & Johnson has entered into a definitive agreement with Numab Therapeutics, a clinical-stage biotechnology company advancing a pipeline of immunology and oncology therapeutics, to acquire the global rights to a novel, investigational first-in-class bispecific antibody, NM26, in an all-cash transaction of approximately $1.25 billion.   NM26, which is ready to enter Phase 2 studies, targets two clinically proven pathways, IL-4R alpha subunit (IL-4Rα) and IL-31, in atopic dermatitis (A...